Consequently, the improving effects of lithium on body weight loss and hyperglycemia were largely abolished by Trig (Figure 7h,i), suggesting that Nrf2 plays a key role in mediating the beneficial effect of lithium therapy in STZ-elicited T1D. The gene discussed is NFE2L2; the disease is Hyperglycemia.